Founded in 1998 in Jerusalem, Israel, Gamida Cell has developed a platform that allows for the expansion of stem cells and natural killer cells while maintaining their original properties. Their products, such as Omidubicel and NiCord, aim to treat high-risk hematologic malignancies, severe aplastic anemia, non-Hodgkin lymphoma, and multiple myeloma. With a diverse pipeline of cell therapies, Gamida Cell is dedicated to bringing life-saving treatment options to patients with significant unmet clinical needs in the field of blood cancers and other diseases.